Ularitide

DRUG3 trials

Sponsors

Facet Biotech, Cardiorentis, University of Aarhus

Conditions

Acute Decompensated Heart FailureAscites HepaticCirrhosis, LiverHeart Failure, Congestive

Phase 1

A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure

WithdrawnNCT00487799

Facet BiotechHeart Failure, Congestive

Target: 32Updated: 2009-07-20

Phase 2

Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.

TerminatedNCT04311489

University of AarhusAscites Hepatic, Cirrhosis, Liver

Start: 2020-08-01End: 2022-11-30Updated: 2023-05-18

Phase 3

Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure

CompletedNCT01661634

CardiorentisAcute Decompensated Heart Failure

Start: 2012-07-31End: 2016-03-31Updated: 2018-10-23

Related Papers

Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure

New England Journal of Medicine2017-04-12306 citations

Rationale for and Design of the TRUE-AHF Trial: The Effects of Ularitide on the Short-Term Clinical Course and Long-Term Mortality of Patients with Acute Heart Failure

European Journal of Heart Failure2016-11-1337 citations